ÑÇÖÞ×ÔοÊÓƵ

Tsewang Tashi
( out of 61 reviews )

Tsewang Tashi, MD

Languages spoken: Tibetan, English, Mandarin Chinese, French, Hindi, Urdu

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-0236

VA - Building #14

Hematology/Oncology
Salt Lake City
801-582-1565

  • Dr. Tsewang Tashi joined the ÑÇÖÞ×ÔοÊÓƵ of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung ÑÇÖÞ×ÔοÊÓƵ, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton ÑÇÖÞ×ÔοÊÓƵ Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects and conducts clinical trials.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 61 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 18, 2024
    HUNTSMAN CANCER CENTER

    Very knowledgeable and takes the time to cover all aspects of your disease and treatment options.

    October 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Fashion makes me feel heard. He listens to my concerns and I feel I have a say in my treatment.

    October 03, 2024
    HUNTSMAN CANCER CENTER

    It was obvious from the first day Dr. Tashi knew my disease and what we could do about it.

    September 06, 2024
    SOUTH JORDAN HEALTH CENTER

    Dr. Tashi is wonderful. He cares so much for his patients. You can tell that he loves the work he does and the people he works with. He is so caring and considerate. I love seeing him. He is always so postive that you leave the exam room feeling like you're very valuable.

    September 05, 2024
    SOUTH JORDAN HEALTH CENTER

    Above and beyond care. He is very knowledgeable but kind and respectful He always gives me hope . Very positive. I love talking with him. Makes things possible.

    September 05, 2024
    HUNTSMAN CANCER CENTER

    Dr Tashi is a rock star. So happy he is there to help us with rare blood disorders.

    July 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Tashi is a great listener and he explained everything in a way that I could understand. I trust his expertise.

    July 25, 2024
    HUNTSMAN CANCER CENTER

    Dr Tashi was vey knowledgeable, informative, and helpful.

    July 06, 2024
    HUNTSMAN CANCER CENTER

    Extraordinario profesional. Incisivo en la búsqueda del origen de tu condición médica que te aqueja.

    See More Patient Comments

  • Dr. Tsewang Tashi joined the ÑÇÖÞ×ÔοÊÓƵ of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung ÑÇÖÞ×ÔοÊÓƵ, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton ÑÇÖÞ×ÔοÊÓƵ Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects and conducts clinical trials.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Master of Science in Clinical Investigation - ÑÇÖÞ×ÔοÊÓƵ of Utah M.S.C.I
    Hematology/Oncology - ÑÇÖÞ×ÔοÊÓƵ of Utah Fellow
    Residency Internal Medicine - Creighton ÑÇÖÞ×ÔοÊÓƵ Resident
    Internal Medicine - Pingtung Christian Hospital Resident
    Internship Internal Medicine - MacKay Memorial Hospital Intern
    Medicine - Chang Gung ÑÇÖÞ×ÔοÊÓƵ School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M (2023). Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid, 2(6), EVIDoa2200339. ()
    2. Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman S (2023). Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer, 23(1), 48. ()
    3. Chuah YY, Tashi T, Kuo CJ (2022). An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. Br J Hosp Med (Lond), 83(11), 1. ()
    4. Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S342-S343. ()
    5. Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237. ()
    6. Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130. ()

    Review

    1. Tashi T, Deininger MW (2023). Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms. [Review]. Immunol Allergy Clin North Am, 43(4), 723-741. ()
    2. Tashi T (2022). Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera. [Review]. Fed Pract, 39(Suppl 2), S43-S46. ()

    Case Report

    1. Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA (2020). Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. Acta Gastroenterol Belg, 83(1), 77-80. ()

    Editorial

    1. Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121. ()

  • News & Podcasts

    Huntsman Cancer Institute News